Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT
Early prophylactic NK cell infusions post-HSCT are safe and feasible. Although relapse incidence remains substantial, outcomes appear improved versus historical data. Future randomized trials must confirm clinical benefits and refine timing/dosing strategies.
Authors
- Davoud Babakhani
- Soroush Rad (ORCID: https://orcid.org/0000-0003-3339-1389)
- Shima Tavoosi
- Ghasem Janbabai
- Shirin Tavakoli (ORCID: https://orcid.org/0000-0001-8016-6403)
- Amir Hossein Baghsheikhi
- Maryam Samareh Salavatipour (ORCID: https://orcid.org/0000-0002-2920-9989)
- Mohammad Ahmadvand (ORCID: https://orcid.org/0000-0002-1429-8165)
- Bahram Chahardouli (ORCID: https://orcid.org/0000-0003-1263-2913)
- Tanaz Bahri (ORCID: https://orcid.org/0000-0001-5725-3592)
- Maryam Barkhordar (ORCID: https://orcid.org/0000-0002-8121-2819)
- Hossein Salehi‐Shadkami
- Seied Asadollah Mousavi
- Mohammad Vaezi (ORCID: https://orcid.org/0000-0002-3186-5491)
Institutions
- Islamic Azad University, Science and Research Branch (IR)
- University of Isfahan (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1186/s12885-025-15362-8
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00